SUN-523 XLH Outcome Data from One Centre Experience with Burosumab

X-linked hypophosphataemia (XLH) is a rare, genetic, chronically debilitating and deformative bone disease that profoundly impacts the affected individual’s day-to-day functioning and quality of life. High levels of circulating fibroblast growth factor 23 (FGF23) lead to excess urinary phosphate exc...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Endocr Soc
Hlavní autoři: Cheung, Moira, Sakka, Sophia, Gilbey-Cross, Robyn, Harries, Mark, Mathieson, Leigh
Médium: Artigo
Jazyk:Inglês
Vydáno: Endocrine Society 2019
Témata:
Bone and Mineral Metabolism
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553073/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-523
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky